$AMGN Company News Amgen's stock drops after t
Post# of 102254
Posted On: 11/12/2014 2:07:48 PM
$AMGN Company News
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view 4:06 p.m. Oct. 27, 2014 - Russ Britt
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Today - Zacks.com
UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New Drugs 8:17 a.m. Today - benzinga.com
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Today - 247WallSt.com
Earnings Triple Plays 2:54 a.m. Today - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3:03 p.m. Nov. 11, 2014 - benzinga.com
Amgen Fights To Protect Neupogen's Exclusivity 12:31 p.m. Nov. 11, 2014 - Seeking Alpha
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog 11:50 a.m. Nov. 11, 2014 - Zacks.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
Big Cap 20 Stuffed With Medical Names 6:34 p.m. Nov. 10, 2014 - Investors Business Daily
Big Cap 20 Stuffed With Medical Names 6:34 p.m. Nov. 10, 2014 - Investors Business Daily
FDA OK with Amgen's BLA for cholesterol-lowering drug 11:02 a.m. Nov. 10, 2014 - Seeking Alpha
Hess Corporation Tops Best Value Long-Term Bond Ranking 9:58 a.m. Nov. 9, 2014 - Seeking Alpha
Dividend Growth Strategy: Take The Beaten Path Or Road Less Traveled? 2:52 p.m. Nov. 6, 2014 - Seeking Alpha
Coherus Bio stumbles in debut 1:59 p.m. Nov. 6, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: BMY, AMGN, MCD 12:59 p.m. Nov. 6, 2014 - TheStreet.com
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
Biosimilars: The Good, the Bad and the Unknown 7:27 a.m. Nov. 6, 2014 - Barrons.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Today - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth 2:24 p.m. Nov. 10, 2014 - PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab 9:15 a.m. Nov. 10, 2014 - PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing 7:01 a.m. Nov. 10, 2014 - GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference 4:30 p.m. Nov. 6, 2014 - PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 4:01 p.m. Nov. 6, 2014 - PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer 9:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors 7:00 a.m. Nov. 4, 2014 - GlobeNewswire
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model 5:30 a.m. Nov. 3, 2014 - BusinessWire - BZX
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire 9:15 a.m. Oct. 30, 2014 - PR Newswire - PRF
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease 4:00 p.m. Oct. 28, 2014 - PR Newswire - PRF
Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans 8:48 a.m. Oct. 28, 2014 - PR Newswire - PRF
Global and China Monoclonal Antibody Industry Report, 2014-2019 9:26 p.m. Oct. 27, 2014 - PR Newswire - PRF
Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30 4:01 p.m. Oct. 27, 2014 - PR Newswire - PRF
Amgen To Webcast 2014 Business Review Meeting On October 28 5:39 p.m. Oct. 23, 2014 - PR Newswire - PRF
Global Pediatric Drugs and Vaccines Market 5:08 p.m. Oct. 23, 2014 - PR Newswire - PRF
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view 4:06 p.m. Oct. 27, 2014 - Russ Britt
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Today - Zacks.com
UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New Drugs 8:17 a.m. Today - benzinga.com
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Today - 247WallSt.com
Earnings Triple Plays 2:54 a.m. Today - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3:03 p.m. Nov. 11, 2014 - benzinga.com
Amgen Fights To Protect Neupogen's Exclusivity 12:31 p.m. Nov. 11, 2014 - Seeking Alpha
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog 11:50 a.m. Nov. 11, 2014 - Zacks.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
Big Cap 20 Stuffed With Medical Names 6:34 p.m. Nov. 10, 2014 - Investors Business Daily
Big Cap 20 Stuffed With Medical Names 6:34 p.m. Nov. 10, 2014 - Investors Business Daily
FDA OK with Amgen's BLA for cholesterol-lowering drug 11:02 a.m. Nov. 10, 2014 - Seeking Alpha
Hess Corporation Tops Best Value Long-Term Bond Ranking 9:58 a.m. Nov. 9, 2014 - Seeking Alpha
Dividend Growth Strategy: Take The Beaten Path Or Road Less Traveled? 2:52 p.m. Nov. 6, 2014 - Seeking Alpha
Coherus Bio stumbles in debut 1:59 p.m. Nov. 6, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: BMY, AMGN, MCD 12:59 p.m. Nov. 6, 2014 - TheStreet.com
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
Biosimilars: The Good, the Bad and the Unknown 7:27 a.m. Nov. 6, 2014 - Barrons.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Today - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth 2:24 p.m. Nov. 10, 2014 - PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab 9:15 a.m. Nov. 10, 2014 - PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing 7:01 a.m. Nov. 10, 2014 - GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference 4:30 p.m. Nov. 6, 2014 - PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 4:01 p.m. Nov. 6, 2014 - PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer 9:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors 7:00 a.m. Nov. 4, 2014 - GlobeNewswire
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model 5:30 a.m. Nov. 3, 2014 - BusinessWire - BZX
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire 9:15 a.m. Oct. 30, 2014 - PR Newswire - PRF
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease 4:00 p.m. Oct. 28, 2014 - PR Newswire - PRF
Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans 8:48 a.m. Oct. 28, 2014 - PR Newswire - PRF
Global and China Monoclonal Antibody Industry Report, 2014-2019 9:26 p.m. Oct. 27, 2014 - PR Newswire - PRF
Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30 4:01 p.m. Oct. 27, 2014 - PR Newswire - PRF
Amgen To Webcast 2014 Business Review Meeting On October 28 5:39 p.m. Oct. 23, 2014 - PR Newswire - PRF
Global Pediatric Drugs and Vaccines Market 5:08 p.m. Oct. 23, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼